Haemonetics (HAE) | Stock Overview & Key Data
Haemonetics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $142.11 on February 8, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Haemonetics HAE | 3.72B Mid-cap | 1.68% | 8.19% | 27.02% | 1.11% | -1.12% | -16.13% | 18.54% | -17.42% |
| Abbott Laboratories ABT | 233.32B Mega-cap | -0.66% | -0.13% | 4.86% | 18.62% | 17.44% | 27.96% | 22.55% | 34.37% |
| Boston Scientific BSX | 154.34B Large-cap | -0.65% | 2.92% | 6.40% | 8.52% | 15.19% | 31.82% | 172.73% | 171.57% |
| Masimo MASI | 8.85B Mid-cap | -3.46% | -3.76% | 0.51% | -0.61% | -1.87% | 45.01% | 26.98% | -30.90% |
| Globus Medical GMED | 7.70B Mid-cap | -5.38% | -5.02% | -22.85% | -34.18% | -29.96% | -20.36% | 0.46% | 16.75% |
| Bio-Rad BIO.B | 7.10B Mid-cap | 0.00% | 0.00% | 3.34% | -26.66% | -23.19% | -11.77% | -49.77% | -49.64% |
Ownership & Short Interest
Haemonetics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Haemonetics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
What is HAE's 52-week high and low?
In the last 52 weeks, Haemonetics reached a high of $94.99 (on November 12, 2024) and a low of $55.30 (on April 9, 2025).
What is the market cap and P/E ratio for HAE?
Curious about Haemonetics's size and valuation? Its market capitalization stands at 3.72B. When it comes to valuation, the P/E ratio (trailing twelve months) is 23.42, and the forward P/E (looking ahead) is 14.52.
Does HAE pay dividends? If so, what's the yield?
As for dividends, Haemonetics isn't currently offering a significant yield, or that specific data isn't available right now.
Who are Haemonetics's main competitors or similar companies to consider before investing?
When looking at Haemonetics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
| Company | Mkt Cap | Sector | Industry | 1Y Return | 3Y Return |
|---|---|---|---|---|---|
| Abbott Laboratories ABT | 233.32B | Healthcare | Medical Devices | 27.96% | 22.55% |
| Boston Scientific BSX | 154.34B | Healthcare | Medical Devices | 31.82% | 172.73% |
| Masimo MASI | 8.85B | Healthcare | Medical Devices | 45.01% | 26.98% |
| Globus Medical GMED | 7.70B | Healthcare | Medical Devices | -20.36% | 0.46% |
| Bio-Rad BIO.B | 7.10B | Healthcare | Medical Devices | -11.77% | -49.77% |
For a more comprehensive list, please see the Peer Performance Comparison table on this page.
What are the key financial health indicators for Haemonetics Corporation? (e.g., ROE, Debt/Equity)
To get a sense of Haemonetics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 18.83%, the Debt to Equity ratio from the most recent quarter is 156.35, and its Gross Profit Margin stands at 58.39%.
What is the recent revenue and earnings growth for HAE?
Looking at Haemonetics's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by -3.70%, and quarterly earnings saw a YoY growth of 184.70%.
How much of HAE stock is held by insiders and institutions?
Wondering who owns Haemonetics stock? Company insiders (like executives and directors) hold about 1.11% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 118.44%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.